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E-mail: famingpan@ahmu.edu.cnLong non-coding RNA (lncRNA) H19 is associated with in-
flammatory diseases, but the molecular mechanism of H19 in
the inflammatory process of ankylosing spondylitis (AS) is un-
clear. Here, we investigated the role of H19 and its downstream
molecules in the inflammation of AS by microarray analysis,
qRT-PCR, western blot, and dual-luciferase reporter assay.
H19 small interfering RNA (siRNA) (Si-H19) and adenovirus
(AD-H19) were used to decrease and increase H19 expression,
respectively. 42 annotated lncRNAs were identified, and H19
was overexpressed. H19, vitamin D receptor (VDR), and trans-
forming growth factor b (TGF-b) can bind to microRNA22-5p
(miR22-5p) and miR675-5p. Si-H19 significantly downregu-
lated miR22-5p and upregulated miR675-5p expression;
Si-H19 decreased the protein and mRNA expression of VDR
and decreased the cytokine and mRNA levels of interleukin-
17A (IL-17A) and IL-23. These results were verified by AD-
H19. In addition, miR22-5p and miR675-5p inhibitors
increased the protein and mRNA expression of VDR and
increased the cytokine and mRNA levels of IL-17A and IL-23.
These results were also confirmed by miRNA mimics. Further-
more, H19 directly interfered with miR22-5p and miR675-5p
expression, whereas the two miRNAs directly inhibited VDR
expression. Overall, the H19-miR22-5p/miR675-5p-VDR-IL-
17A/IL-23 signaling pathways have important roles in the path-
ogenesis of AS.
INTRODUCTION
Ankylosing spondylitis (AS) is a form of inflammatory arthritis of the
spine and sacroiliac joint that is highly heritable and familial. Large-
scale studies in different populations have identified many genetic
polymorphisms and inflammatory pathways related to the etiology
and pathogenesis of AS,1–6 but the detailed mechanisms for the
underlying inflammatory process of AS remain unclear. Non-coding
RNAs (ncRNAs) account for more than 80% of human genomic
transcripts and involved in many biological processes including tran-
scriptional and post-transcriptional regulation, mRNA stability andMolecular The
This is an open access article under the CC BY-NC-translation, and protein degradation and transport.7 However, few
studies have investigated the role of ncRNAs in AS.
MicroRNA (miRNA) is a small ncRNA containing about 20 nucle-
otides that downregulates the expression of target genes by medi-
ating mRNA decay and inhibiting translation.8 Increasing studies
have shown that miRNAs play an important role in cellular func-
tion and inflammation. Abnormal miRNA expression has been
observed in peripheral blood mononuclear cells (PBMCs) and
T cells in AS patients.9–11 Nonetheless, little is known about the up-
stream regulator of miRNA, which may have the potential to block
the inflammatory pathway of AS. Long ncRNA (lncRNA) is a class
of single-stranded ncRNAs with more than 200 nucleotides. It is
transcribed and processed like mRNA but it cannot encode func-
tional proteins. Hitherto, the functions of many lncRNAs are rarely
known.12
Recently, lncRNAs have been considered as competing endogenous
RNAs (ceRNAs) that sponge miRNAs’ complementary base pair-
ing.13–15 lncRNAH19 activates osteoblast differentiation via activating
Wnt/b-catenin signal pathway by acting as a ceRNA for miR22 and
miR141.15 In addition, H19 can act as an upstreammolecule of miRNA
to regulate mRNA expression, and miR675-5p is transcribed from the
first exon of H19 and has been validated to play an important role in
some diseases.16,17 These findings strongly support the regulatory
role of H19 in the development of inflammatory diseases.18 Vitamin
D receptor (VDR) is a nuclear receptor that mediates the production
of 1,25(OH)2D3, and transforming growth factor b (TGF-b) is a multi-
functional cytokine involved in regulation and cell proliferation.rapy: Nucleic Acids Vol. 19 March 2020 ª 2019 The Author(s). 393
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Differentially Expressed lncRNAs, and Bioinformatics Analysis
(A) Hierarchical cluster analysis showed distinguishable expression of lncRNAs between patients and controls. Each row represents one lncRNA (A1–A5 and C1–C5
represent an individual code of patients and controls, respectively), and each column corresponds to the expression profile of one sample. Red pixels indicate higher
expression of genes, whereas green pixels indicate lower expression. (B) Volcano plot of lncRNAs. The abscissa is log2 (2.0-FC in expression), and the ordinate is –log10
(p value). The red and blue dots correspond to genes that are upregulated and downregulated, respectively, the green dots correspond to genes with an absolute value < 2 in
FC, and the black dots correspond to those genes that are not significantly different (A and C represent the individual code of patients and controls, respectively). (C–E)
Schematic diagrams of mutual interplays between H19 and miR675-5p/miR22-5p (C), miR675-5p and VDR/TGF-b (D), and miR22-5p and VDR/TGF-b (E). The positions of
miRNA binding sites and the calculated DG values are shown (kcal/mol).
Molecular Therapy: Nucleic AcidsPrevious studies have shown that VDR and TGF-b have important
roles in inflammation and AS,17,19,20 and their relationship with H19
and miRNA has been well investigated in the development of inflam-
matory diseases.17,21 In patients with ulcerative colitis, H19 overexpres-
sion may decrease the expression of VDR, and H19 promotes osteo-
blast differentiation and enhances heterotopic bone formation via
activating TGF-b/Smad3/HDAC pathway by deriving miR675.21
A number of differentially expressed (DE) lncRNAs have been iden-
tified in AS patients.22–29 However, it is unclear how lncRNA and its
downstream molecules affect the development of AS. In addition, an
online-based program RNAhybrid (https://bibiserv.cebitec.uni-
bielefeld.de/rnahybrid/) found that miR22-5p and miR675-5p bind-
ing sites of H19, VDR, and TGF-b; IL-17A, IL-23, and tumor necrosis
factor alpha (TNF-a) play important roles in the pathogenesis of
AS.30–33 In this study, we investigated the role of H19 and its down-
stream signaling molecules in the inflammatory process of AS.394 Molecular Therapy: Nucleic Acids Vol. 19 March 2020RESULTS
lncRNA Expression Profiles of Peripheral Blood Mononuclear
Cell of AS
To identify DE lncRNAs in peripheral blood mononuclear cells
(PBMCs) of AS, we carried out lncRNA expression profiles in 5 AS
patients and 5 healthy controls (HCs) using lncRNA microarray.
Heatmap and volcano plots showed that lncRNAs distinguished AS
patients from HCs (Figures 1A and 1B). A total of 154 lncRNAs
were DE in PBMCs (fold change [FC] > 2, p < 0.05), including 71
lncRNAs that were upregulated, 83 that were downregulated, and
42 that were annotated (Table S1).
Bioinformatics Analysis
To explore whether VDR and TGF-b could be regulated by
miRNA, we first analyzed the 30 UTR of VDR and TGF-b using
the RNAhybrid online program34 and found several potential
miRNA-binding sites. Similarly, we used the program to predict
Figure 2. Determination of Candidate lncRNA and Its Correlation with mRNAs
(A–D) Relative expression of H19 (A), LOC101929023 (B), LINC00320 (C), and ZRANB2-AS2 (D) between AS and HC. (E and F) ROC results of H19 (E) and LOC101929023
(F). (G) Expression of VDR, TGF-b, IL-17A, IL-23, and TNF-a. (H–L) Correlation analysis between H19 and VDR (H), TGF-b (I), IL-17A (J), IL-23 (K), and TNF-a (L). *p < 0.05;
NS, not significant as compared with the HC group. AS, ankylosing spondylitis; AUC, area under curve; HC, healthy control; ROC, receiver operating characteristic.
www.moleculartherapy.orgthe binding sites H19 and miRNAs. According to bioinformatics
results and previous studies,15,17,21 miR22-5p and miR675-5p were
selected as the target molecules for H19 (Figure 1C) and VDR and
TGF-b as the targets for miR22-5p and miR675-5p (Figures 1D
and 1E).
Validation of DE lncRNAs in PBMCs
Subsequently, four lncRNAs were selected to verify the
microarray results using qRT-PCR in 49 AS patients and 49
HCs. lncRNA H19 and LOC101929023 (Figures 2A and 2B) but
not LINC00320 or ZRANB2-AS2 (Figures 2C and 2D) were
significantly overexpressed in AS patients compared to HCs,
suggesting that H19 and LOC101929023 are really DE lncRNAs
in AS. To further determine the most representative lncRNA,
we performed receiver operating characteristic (ROC) curve ana-
lyses on the two dysregulated lncRNAs and found that H19
had a higher area under curve (AUC) and a greater power
(p value) than LOC101929023 (Figures 2E and 2F), suggesting
that the diagnostic value of H19 is greater than LOC101929023.
Therefore, H19 was selected as the target lncRNA for the next
investigations.mRNA Expression in PBMC
In addition to validating the microarray results, we also measured the
mRNA expression of VDR, TGF-b, IL-17A, IL-23, and TNF-a in the
same cohort of 49 patients and 49 HCs. We found that the expression
of VDR and IL-17A but not the other three mRNAs was significantly
higher in AS patients compared to HCs (Figure 2G), indicating that
VDR and IL-17A are important for the inflammation of AS. Further-
more, we carried out correlation analyses to explore the potential
relationship between H19 and the five mRNAs. We found that the
expression of H19 was positively associated with the mRNAs, and
these associations provide clues to further explore the regulatory
function of H19, although they are weak (Figures 2H–2L).
H19 Regulates the Target Molecules in PBMCs
To explore the role of H19 in the inflammatory responses, we changed
the expression of H19 (i.e., H19 knockdown and overexpression) in
PBMC. First, we designed three specific siRNA sequences (coded as
Si-H19-1484, Si-H19-814, and Si-H19-595) to inhibit H19 expression
and used a negative control (NC) as the internal control group.
Compared to the NC group, both Si-H19-1484 and Si-H19-814 but
not Si-H19-595 significantly downregulated H19 expression, andMolecular Therapy: Nucleic Acids Vol. 19 March 2020 395
Figure 3. H19 Regulates Target Molecules
(A) Si-H19-1484 and Si-H19-814 but not Si-H19-595 significantly decreased the expression of H19. (B–D) Si-H19 significantly increased the expression of miR22-5p and
decreased the expression of miR675-5p (B), VDR (C), IL-17A (D), and IL-23 (D). (E–H) AD-H19 significantly increased the expression of H19 (E), decreased the expression of
miR22-5p (F), and increased the expression of VDR (G) and IL-17A (H). *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001; NS, not significant as compared with the NC group.
AD-H19, H19 overexpression; Si-H19, H19 knockdown; NC, negative control.
Molecular Therapy: Nucleic Acidsthe knockdown effect of Si-H19-1484 was stronger (Figure 3A).
Therefore, we used Si-H19-1484 to inhibit H19 expression in subse-
quent experiments. We found that Si-H19 significantly decreased the
expression of miR675-5p and VDR and increased the expression of
miR22-5p (Figures 3B and 3C). In addition, Si-H19 significantly
decreased the mRNA expression of IL-17A and IL-23 but not
TNF-a (Figure 3D).
Second, to confirm the above findings, PBMCs were transfected with
H19-associated adenovirus (AD-H19) to increase the expression of
H19. Compared to the NC group, AD-H19 significantly increased
the expression of H19 (Figure 3E), suggesting that AD-H19 is effec-
tive. In contrast to the Si-H19 results, AD-H19 increased the expres-
sion of VDR and IL-17 and decreased the expression of miR22-5p
(Figures 3F–3H). These findings indicated that H19 has an important
role in the development of AS by regulating miR22-5p, miR675-5p,
and VDR, which needs further validation.
miRNAs Regulate Target Molecules and Reverse Regulate H19
in PBMCs
To further investigate the role of H19 and its downstream molecules,
we transfected PBMCs with miRNA mimics (i.e., miR22-5p and
miR675-5p mimics) and miRNA inhibitors (i.e., miR22-5p and
miR675-5p inhibitors) to increase and decrease the expression
of miRNAs, respectively. First, the expression of miR22-5p and
miR675-5p was increased by miRNA mimics and decreased by
miRNA inhibitors (Figures 4A and 4E), suggesting that these mimics
and inhibitors are useful. Second, to explore the effects of the two396 Molecular Therapy: Nucleic Acids Vol. 19 March 2020miRNAs on H19, we measured the expression of H19 when cells
were transfected with miRNA mimics and inhibitors. The two
miRNA inhibitors significantly increased H19 expression, and only
miR22-5p mimics decreased H19 expression (Figures 4B and 4F),
suggesting that miRNAs have a negative feedback role in H19. Third,
miR22-5p mimics decreased the mRNA expression of VDR, TGF-b,
IL-17A, and IL-23, whereas miR22-5p inhibitors increased their
expression levels (Figures 4C and 4D); miR675-5p mimics and inhib-
itors had similar findings in all molecules except for TGF-b mRNA
expression (Figures 4G and 4H). Furthermore, the expression of
TNF-a was not changed by the two miRNA mimics and inhibitors,
indicating that TNF-a may not be a key molecule for AS (Figures
4D and 4H). These results suggested that the H19-miRNA (miR22-
5p and miR675-5p)-VDR-IL-17A/IL-23 pathway may play a key
role in AS.
H19 and miRNAs Regulate VDR and TGF-b Proteins in PBMCs
To explore the effects of H19, miR22-5p, and miR675-5p on post-
transcriptional regulation, we measured the protein expression of
VDR and TGF-b using western blot. As expected, the results of pro-
teins were consistent with those of mRNAs. The protein expression of
VDR and TGF-b was significantly decreased by Si-H19 and increased
by AD-H19 (Figures 5A–5C). Moreover, both miR22-5p and
miR675-5p mimics significantly inhibited the protein expression of
VDR and TGF-b, and miR22-5p inhibitors increased their expression
levels (Figures 5D–5I). However, the miR675-5p inhibitors increased
the protein expression of VDR but not TGF-b (Figure 5I). Therefore,
H19, miR22-5p, and miR675-5p have important roles in VDR and
Figure 4. miRNAs Regulate Target Molecules and Reverse the Regulation of H19
(A) Effect of miR22-5p mimics and inhibitors on miR22-5p expression. (B–D) The miR22-5p mimics significantly decreased the expression of H19 (B), VDR (C), TGF-b (C),
IL-17A (D), and IL-23 (D), while the miR22-5p inhibitors increased their expressions. (E) Effect of miR675-5p mimics and inhibitors on miR675-5p expression. (F–H) The
miR675-5p mimics significantly decreased the expression of VDR (G), TGF-b (G), IL-17A (H), and IL-23 (H), while miR675-5p inhibitors increased the expressions of H19 (E),
VDR (G), IL-17A (H), and IL-23 (H). *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001; NS, not significant as compared with the NC group. miR22-M, miR22-5p mimics;
miR22-I, miR22-5p inhibitors; miR675-M, miR675-5p mimics; miR675-I, miR675-5p inhibitors; NC, negative control.
www.moleculartherapy.orgTGF-b proteins, especially VDR protein. Given the above results, two
signaling pathways (H19-miR675-5p-VDR and H19-miR22-5p-
VDR) may be involved in the inflammatory mechanisms of AS.
H19 Directly Regulates miRNAs, and miRNAs Directly Target
VDR
miRNA directly suppresses the expression of target genes8 while
lncRNA acts as a posttranscriptional regulator by interacting with
miRNA via ceRNA or miRNA sponge.13,14 To further investigate
whether H19 is a ceRNA or molecular sponge in the regulation of
miR22-5p and miR675-5p, and to investigate the role of the two miR-
NAs in the regulation of VDR, we performed luciferase reporter gene
assays in HEK293 T cells. Luciferase reporter gene vectors
(i.e., mutant-type named H19-MUT, VDR-MUT containing a muta-
tion at the predicted miR22-5p and miR675-5p and wild-type named
H19-WT, VDR-WT) at the predictedmiR22-5p andmiR675-5p (Fig-
ures 1C–1E) binding sites were constructed, and psiCHECK2 empty
vector is a NC; these vectors were co-transfected into cells with
miR22-5p mimics or miR675-5p mimics.
The luciferase activity of H19-WT and VDR-WT was suppressed by
miR22-5p mimics (Figures 6A and 6B) and miR675-5p mimics (Fig-
ures 6C and 6D); and miR675-5p mimics showed a trend toward
decreasing the luciferase activity of H19-MUT, indicating that the
relationship between H19 and miR675-5p is diverse.15,21 However,
the luciferase activity of H19-MUT and VDR-MUT in cells trans-
fected with the two miRNA mimics showed no statistical differences
(Figures 6A–6D). These findings suggested that H19 and the 30 UTR
of VDR can bind to miR22-5p and miR675-5p and that H19 may
serve as a ceRNA for miR22-5p, interact directly with miR675-5p,and further compete with VDR for miR22-5p and miR675-5p
binding.
H19 and miRNAs Regulate Inflammatory Cytokines in PBMCs
To investigate the effects of H19, miR22-5p, and miR675-5p on key
cytokines in the inflammatory pathway of AS and to further validate
the expression of mRNAs, we measured the level of IL-17A, IL-23,
and TNF-a cytokines in cell supernatants. Si-H19 significantly
decreased the levels of IL-17A and IL-23 cytokines, and AD-H19
significantly increased their levels (Figures 7A and 7B). However,
neither Si-H19 nor AD-H19 altered TNF-a level (Figure 7C).
Although both miRNA inhibitors significantly increased the IL-17A
level, only miR22-5p inhibitors increased the IL-23 level (Figures
7D and 7E). In addition, the two miRNA mimics did not change
the level of IL-17A and IL-23 cytokines, but miR22-5p mimics
reduced TNF-a level (Figures 7D–7F). Taken together, H19,
miR22-5p, and miR675-5p play important roles in the release of
inflammatory cytokines, especially IL-17A and IL-23.
DISCUSSION
In this study, we identified 42 annotated DE lncRNAs in AS patients
where lncRNA H19 was significantly overexpressed. Moreover, H19
increased the release of IL-17A and IL-23 cytokines by competitively
binding to VDR via acting as a ceRNA for miR22-5p and interacting
with miR675-5p. These findings provide new insights into the role of
H19 and its downstream molecules in the pathogenesis and inflam-
matory process of AS.
AS is an inflammatory disease without definitive mechanisms, and
previous microarray and sequencing studies have shown that thereMolecular Therapy: Nucleic Acids Vol. 19 March 2020 397
Figure 5. H19, miR675-5p, and miR22-5p Regulate Protein Expression
(A–C) Effect of H19 on the protein expression of VDR and TGF-b, Si-H19 significantly decreased the protein expression of VDR (B) and TGF-b (C), while AD-H19 significantly
increased their expressions. (D–F) Effect of miR22-5p on the protein expression of VDR (E) and TGF-b (F); miR22-5p inhibitors significantly increased the protein expression of
VDR (E) and TGF-b (F) while miR22-5pmimics decreased their expressions. (G–I) Effect of miR675-5p on the protein expression of VDR (H) and TGF-b (I), miR675-5p inhibitor
increased the protein expression of VDR (H), while miR675-5p mimics decreased the protein expression of VDR (H) and TGF-b (I). *p < 0.05, **p < 0.01, ***p < 0.005, ****p <
0.001; NS, not significant as compared with the NC group. AD-H19, H19 overexpression; Si-H19, H19 knockdown; miR22-M, miR22-5p mimics; miR22-I, miR22-5p
inhibitors; miR675-M, miR675-5p mimics; miR675-I, miR675-5p inhibitors; NC, negative control.
Molecular Therapy: Nucleic Acidsare several DE lncRNAs in AS,26,27 suggesting that the involvement of
lncRNAs in AS, but functionalities of lncRNAs, have not been char-
acterized. In this study, many dysregulated lncRNAs were found in
PBMCs of AS, and the expressions of lncRNAs were detected by
microarray analysis and verified by qRT-PCR, which are routinely
used for identifying RNA.27,35 The two testing methods showed
similar trends, but FCs were not exactly the same. One possible expla-
nation is the different sensitivity of the two assays or the use of
different samples in the two phases.
Our results indicated that H19 and LOC101929023 were substantially
overexpressed in AS patients and the AUC of H19 was higher than
LOC101929023. Therefore, H19 was selected as a candidate lncRNA
in this study. H19 is highly expressed from the early stages of embryo-
genesis throughout fetal life in many tissues and is downregulated
postnatally;36 recent studies found that the H19 regulates cell differ-
entiation and musculoskeletal system regeneration21,37–40 and plays
an important role in inflammatory diseases.17,35,41–43 For example,
H19 expression was higher in synovial tissue from patients with rheu-
matoid arthritis and osteoarthritis compared to controls,41 a microar-
ray analysis revealed 121 DE lncRNAs in osteoarthritis patients and
H19 was upregulated.35 These findings suggest that H19 is a key
molecular in the pathogenesis of inflammatory diseases, and we
expect more studies will be conducted to explore the role of H19 in
other diseases.398 Molecular Therapy: Nucleic Acids Vol. 19 March 2020The bioinformatic analysis found that H19 and the 30 UTR of VDR
and TGF-b can bind to the miR22-5p and miR675-5p, previous
studies have also reported,15,17,21,44 and one single miRNA can target
several mRNAs and one mRNA can also be regulated by many
miRNAs.45,46 Furthermore, H19 was enriched in AGO2 (amajor con-
stituent of the RNA-induced silencing complex), suggesting that H19
is a natural decoy of miRNA.47 More importantly, two different
potential modulatory mechanisms of H19 involved in cell differenti-
ation and inflammatory progression have been investigated47 (see
Figure 8). First, one is that H19 serves as a ceRNA by sponging for
miRNAs, thereby interfering with gene regulatory networks.15,44
Our findings of the overexpression of H19 decreased miR22-5p
expression and increased themRNA expression of VDR, and these re-
sults were confirmed by Si-H19. The protein expression of VDR and
TGF-b was enhanced by AD-H19 and suppressed by Si-H19; these
findings were similar to their mRNAs results, suggesting that H19
can regulate gene expression at the transcriptional and post-tran-
scriptional levels. To further validate the modulatory mechanisms
of H19, we examined whether miR22-5p could inhibit the expression
of H19 and downstream target genes. Our results showed that the
expression of H19 was suppressed by miR22-5p mimics and ampli-
fied by miR22-5p inhibitors, further suggesting that miR22-5p can
reverse the effect of H1915,44 and lncRNA can regulate miRNA and
vice versa. Previous studies found that H19 activated Wnt/b-catenin
signaling by acting as a ceRNA for miR22.15,44 These studies strongly
Figure 6. miR-22-5p and miR675-5p Interact with
H19 and VDR via Direct Binding
(A–D) Wild-type or mutant-type H19 and VDR 30 UTR
luciferase reporter gene vectors were constructed
(named H19-WT, VDR-WT, H19-MUT, and VDR-MUT);
mutant-type vectors contained a mutation at the pre-
dicted miR22-5p (A and B) and miR675-5p binding sites
(C and D). The above vectors were co-transfected into
HEK293T cells with miR22-5p mimics and inhibitors, or
miR675-5p mimics and inhibitors; the luciferase activity
was determined. *p < 0.05, **p < 0.01, ***p < 0.005,
****p < 0.001; NS, not significant as compared with the
NC group. H19-WT, WT H19; H19-MUT, mutant-type
H19; VDR-WT, wild-type VDR; VDR-MUT, mutant-type
VDR; NC, negative control containing psiCHECK2 empty
vector.
www.moleculartherapy.orgsupport the regulating effect of H19 on the disease process and cell
function. Moreover, we found that miR22-5p mimics suppressed
the mRNA level and protein expression of VDR, indicating that
miR22-5p may be a useful regulator of VDR. In addition, the lucif-
erase activity of H19 and VDR was suppressed by miR22-5p mimics,
indicating that H19 directly regulates miR22-5p and miR22-5p regu-
lates VDR. Taken together, H19 regulates the expression of VDR by
acting as a ceRNA of miR22-5p. Second, another regulatory pathway
of H19 is the network of lncRNA-miRNA-mRNA, which means that
H19 modulates mRNA expression by interacting directly with
miRNA. Unlike the relationship between H19 and miR22-5p, we
found that H19 was positively associated with miR675-5p, and
Si-H19 significantly decreased the expression of miR675-5p. We
did not detect the effects of H19 and miR675-5p on the mRNA
expression of TGF-b. However, H19 significantly altered the protein
expression of TGF-b, and miR675-5p mimics slightly decreased the
protein expression of TGF-b, indicating that miR675-5p regulation
of the protein expression of TGF-b may be partially mediated by
H19. Moreover, certain lncRNAs encode miRNAs and work together
to achieve regulatory functions. miR675-5p is encoded by the first
exon of H19 and acts as a cooperator of H19 in the regulation of
cellular differentiation,15,48 but their relationship is mixed. H19 and
miR675 were significantly upregulated in osteogenic differentiation
and inhibited the mRNA and protein expression of TGF-b.21
However, another study has shown that miR675-5p makes a negative
regulatory feedback loop by target binding site of H19 in osteogenic
differentiation.15 H19 was inhibited by ectopic transfection of
miR675-5p, and the overexpression of miR675-5p suppressed the
luciferase activity of H19.15 These findings suggest that the roles of
miR675-5p are diverse and the regulatory relationship between H19
and miR675-5p in inflammation needs further confirmation. We first
investigated the role of VDR and the H19-miR675-5p-VDR pathway
in the inflammation and pathogenesis of AS. The overexpression of
H19 and miR675-5p mimics increased the mRNA level and protein
expression of VDR in PBMCs. While in ulcerative colitis tissues,
H19 overexpression decreased VDR expression, and this effect
was significantly attenuated by co-transfection with miR675 inhibi-
tor.17 Moreover, the luciferase activity of H19 and VDR was sup-
pressed by miR675-5p mimics. Taking into account the findings ofH19-miR22-5p-VDR, these results further indicate that H19 is very
important for the regulation of gene transcription and translation,
future studies should focus on the role of signal pathways in AS
and other inflammatory diseases.
Differs from the experiments of Transwell and wound healing in
tumor research, we measured the mRNA expressions and cytokine
levels of IL-17A, IL-23, and TNF-a in AS patients. Of the three cyto-
kines, IL-17A is the most important to the inflammation of AS. The
mRNA expression and cytokine levels of IL-17A were significantly
increased by AD-H19, miR22-5p, andmiR675-5p inhibitors, and these
results were further confirmed by Si-H19 and miRNAs mimics. IL-23
but not TNF-a had similar results, indicating that the IL-17A/IL-23
signaling has an important role in the inflammatory progression of
AS. IL-17 and IL-23 levels were elevated in serum and PBMCs superna-
tants in AS patients, and IL-23 could stimulate IL-17 production, indi-
cating that IL-17 is strongly associated with IL-23,49 and bone changes
inASpatientswere the combined effects of IL-23 and IL-17A.50 Intrigu-
ingly, TGF-b and VDR are thought to be important regulators of the
inflammatory response process,51–53 and VDR and TGF-b signaling
pathways also play vital roles in the downstream cytokines including
TNF-a and IL families. Taken together, we hypothesized that the
abnormal expression of H19 alters mRNA expression by changing
miRNAs’ status in two different ways to increase IL-17A and IL-23
release in PBMCs, which may then enter into the spine to cause or
exacerbate the inflammatory response of AS (Figure 8).
Our research includes several strengths. First, we developed a DE
lncRNAs profile in AS patients and investigated the role of H19
and its downstream pathways in the inflammatory responses of AS.
Second, PBMCs were directly extracted from human peripheral blood
rather than purchased from cell lines. Human inflammation and
immune-associated cells should be considered to explore the effects
of our findings on AS in the future. In addition, PBMCs are easy to
collect and low cost, so the detection of H19 in PBMCs may be widely
used to identify AS patients in larger sample sizes. Previous studies
suggested that disease progression is often accompanied by changes
in biomarkers, which can provide guidance for the treatment of dis-
ease.54 However, some limitations should be considered. First, theMolecular Therapy: Nucleic Acids Vol. 19 March 2020 399
Figure 7. H19, miR675-5p, and miR22-5p Regulate Cytokine Levels
(A–C) AD-H19 significantly increased the level of IL-17A (A) and IL-23 (B) cytokines and Si-H19 decreased their levels, but the level of TNF-a cytokine (C) did not change when
cells were transfected with adenovirus and siRNA. (D–F) miR22-5p andmiR675-5p inhibitors significantly increased the level of IL-17A cytokines (D), and miR22-5p inhibitors
increased the level of IL-23 cytokines (E), and miR22-5p mimics decreased the level of TNF-a cytokines (F). *p < 0.05, ***p < 0.005, ****p < 0.001; NS, not significant as
compared with the NC group. AD-H19, H19 overexpression; Si-H19, H19 knockdown; miR22-M, miR22-5p mimics; miR22-I, miR22-5p inhibitors; miR675-M, miR675-5p
mimics; miR675-I, miR675-5p inhibitors; NC, negative control.
Molecular Therapy: Nucleic Acidsunderlying mechanisms of H19-associated pathways in different cell
types contributing to AS pathogenesis need to be explored. Second,
the role of TGF-b in the inflammatory response needs further valida-
tion. Finally, our results should be verified in animal models and other
populations.
In conclusion, H19 is overexpressed in AS patients and mediates
inflammatory progression by acting as a ceRNA in the axis of
H19-miR22-5p-VDR-IL-17A/IL-23 and interaction with miRNA in
the axis of H19-miR675-5p-VDR-IL-17A/IL-23. This study lays an
important foundation for further understanding of the pathogenesis
of AS and H19 may be a usefully diagnostic and therapeutic
biomarker for AS.
MATERIALS AND METHODS
Subjects
Patients diagnosed with AS according to the 1984 modified New York
criteria of the American College of Rheumatology were enrolled from
the Department of Rheumatology and Immunology. Patients were
excluded if they had been diagnosed with other inflammatory autoim-
mune diseases such as inflammatory bowel disease or rheumatic dis-
ease. Age- and sex-matched HCs without a history of autoimmune
and chronic diseases were enrolled from the local community. Five
pairs of AS patients and HCs were included for the screening of DE
lncRNA using human lncRNA microarray, 49 pairs for lncRNA
verification and mRNAs detection (i.e., VDR, TGF-b, IL-17A, IL-
23, and TNF-a) using qRT-PCR, and 8 AS patients for functional400 Molecular Therapy: Nucleic Acids Vol. 19 March 2020experiments. All participants provided written informed consent.
This study was approved by the ethics committee of Anhui
Medical University. Clinical characteristics of subjects are listed in
Table S2.
PBMCs Extraction and Cell Culture
PBMCs were extracted from peripheral venous blood using a stan-
dard Ficoll-Hypaque density gradient centrifugation method accord-
ing to the protocol. PBMCs were cultured in RPMI-1640medium (In-
vitrogen-GIBCO, USA) using 12-well culture dishes containing 10%
fetal bovine serum, 100 U/mL penicillin, and 100 U/mL streptomycin.
PBMCs were stimulated with phytohemagglutinin (PHA)55,56 at 37C
and 5% CO2 to increase the number of cells. Cell viability was
measured using a 0.4% trypan blue solution. Cells were harvested af-
ter incubation, and supernatants were collected and stored at 80C
for ELISA.
lncRNA Microarray Analysis
The protocol of Arraystar lncRNA array is as follows: (1) preparation,
clearance, and quality control of RNA; (2) preparation of labeling re-
actions; (3) purification of labeled/amplified RNA and quality control
of labeled cRNA; (4) hybridization; (5) microarray cleaning; (6) scan-
ning; and (7) data extraction. The complementary DNA (cDNA) was
labeled and hybridized using the 4 180 K human lncRNA microar-
ray (Agilent, USA) designed for 89,459 lncRNA probes. DE genes
with p < 0.05 and FC > 2 were selected. All microarray analyses
were performed by the OE Biotech Company (Shanghai, China).
Figure 8. Regulatory Mechanisms of H19 in AS
Dual signaling pathways (H19-miR22-5p-VDR and H19-
miR-675-5p-VDR) are involved in the pathogenesis and
inflammatory process of AS. One of them is that H19
serves as a ceRNA to sponge miR22-5p by RNA-induced
silencing complex (RISC), and another is that H19 directly
interacts with miR675-5p. These two pathways affect the
expression of VDR and increase the release of IL-17A and
IL-23 cytokines, followed by the two cytokines infiltrating
the spine and causing or exacerbating the inflammatory
response.
www.moleculartherapy.orgBioinformatics
Online-based RNAhybrid (https://bibiserv.cebitec.uni-bielefeld.de/
rnahybrid/) program was used to predict binding sites for H19,
VDR, and TGF-b potentially associated with miR675-5p and
miR22-5p. Bioinformatics analyses were carried out by the Gene
Pharma Company (Shanghai, China).qRT-PCR for Detection of lncRNA and mRNA
Total RNA was extracted from PBMCs using the miRNeasy Kit
(QIAGEN, Germany) and reverse transcribed into cDNA using the
PrimeScript RT reagent kit (Takara Bio, Japan) according to the
recommendations. The purity and concentration of RNA were deter-
mined by UV absorbance at 260 and 280 nm using the NanoDrop
2000 Spectrophotometer (NanoDrop Technologies, DE, USA).
qRT-PCR reaction was performed in duplicate using the ABI ViiA
7 Real-Time PCR System (Applied Biosystems, Foster City, CA,
USA) and the SYBR Premix Ex Taq II (Takara Bio, Japan) according
to themanufacturer’s instructions. All reactions were performed in an
8-strip tube at 95C for 1 min, followed by 42 cycles at 95C for 10 s,
60C for 30 s, and 72C for 1 min; melt curve stage was then per-
formed to detect specific amplification at 95C for 15 s, 60C for
1 min, and 95C for 15 s. RNA relative expression was calculated as
FC using the 2-DDCt comparative threshold cycle method, and b-actin
was used as an internal control. The primers of forward (F) and
reverse (R) are listed in Table S3.Molecular ThqRT-PCR for Detection of miRNA
miRNA was extracted from PBMCs using the
miRNeasy Mini Kit (QIAGEN, Germany) and
reverse transcribed into cDNA using the
miScript II RT kit (QIAGEN, Germany) ac-
cording to the manufacturer’s instructions.
The purity and concentration of RNA were
determined by UV absorbance at 260 and
280 nm using the NanoDrop 2000 Spectropho-
tometer (NanoDrop Technologies, DE, USA).
qRT-PCR was performed in duplicate on an
ABI ViiA 7 Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA) using the
miScript SYBR Green PCR Kit (QIAGEN, Ger-
many). All reactions were performed in an 8-strip tube at 95C for 15 min, followed by 42 cycles at 95C for 15
s, 55C for 30 s, and 72C for 30 s; melt curve stage was then per-
formed to detect specific amplification at 95C for 15 s, 60C for
1 min, and 95C for 15 s. RNA relative expression was calculated as
FC using the 2-DDCt comparative threshold cycle method, and U6
was used as an internal control. The primers of forward (F) and
reverse (R) are listed in Table S3.
Western Blot
The harvested PBMCs were washed with phosphate buffered saline
(PBS) and lysed with a protease inhibitor cocktail in a radioimmuno-
precipitation assay (RIPA) lysis buffer (Beyotime, Shanghai, China).
Total proteins in the lysate were separated by sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to polyvinylidene difluoride (PVDF) membranes (Millipore, Brad-
ford, MA, USA). Subsequently, the membranes were blocked with
5% non-fat milk in Tris-Buffered Saline Tween (TBST) (50 nM
Tris-HCl, 150 mM NaCl, 0.05% Tween 20, pH 7.5) for 1 h at room
temperature, followed by incubation with primary antibodies at
4C for overnight. The primary antibodies were anti-VDR (1:1,000,
Cell Signaling Technology, MA, USA), anti-TGF-b (1:1,000, Cell
Signaling Technology, MA, USA), and anti-b-actin (1:1,000, Cell
Signaling Technology, MA, USA), and anti-b-actin antibody was
used as a control. The blots were washed with TBST three times
and then incubated with secondary horseradish peroxidase-conju-
gated antibody (1:5,000 dilution, Biotechnology, Santa Cruz, CA,erapy: Nucleic Acids Vol. 19 March 2020 401
Molecular Therapy: Nucleic AcidsUSA) for 4 h at room temperature. An enhanced chemo-lumines-
cence detection kit (ECL Advance, UK) was used to expose the film
and visualize chemiluminescence. Densitometry of all proteins was
normalized against the loading control. Protein bands were calculated
using the ImageJ software (NIH, Bethesda, MD, USA).ELISA
Concentrations of IL-17A, IL-23, and TNF-a in the cell supernatants
were measured using human ELISA kits (CUSABIO Life Sciences,
MD, USA) according to the manufacturer’s recommendations.
Briefly, 96-well fat-bottomed high-binding ELISA plates were coated
with anti-human IL-17A, IL-23, and TNF-a. Samples and standards
were added in plates at 37C for 2 h and then washed with PBS-T,
PBS, and 0.05% Tween-20. After that, they were coated with bio-
tinylated antibody, washed with PBS-T, and avidin-HRP conjugate
was added. The above operation was repeated. Colorimetric reactions
were incubated with tetramethylbenzidine and terminated with sulfu-
ric acid. Optical density was detected at 450 nm on the microplate
reader (Thermo Fisher Scientific, Waltham, MA, USA) and the con-
centration was calculated using standard curve interpolation.Transfection
H19 adenovirus (AD-H19), H19 siRNA (Si-H19), and miRNA
mimics and inhibitors were purchased from the Gene Pharma Com-
pany (Shanghai, China). We designed three siRNA sequences (coded
as Si-H19-595, Si-H19-1484, Si-H19-814) to knock down the expres-
sion of H19, and AD-H19 was applied to upregulate the expression of
H19. In addition, miR22-5p and miR675-5p mimics were used to up-
regulate the expression of miRNA, miR22-5p, and miR675-5p inhib-
itors to downregulate their expressions.When cells reached 70%–80%
confluence, they were seeded in 12-well plates and were transfected
with AD-H19, Si-H19, and miRNA mimics and inhibitors using
Lipofectamine 3000 according to the manufacturer’s instructions.
The sequences of Si-H19, AD-H19, miRNA mimics, and inhibitors
are listed in Table S4.Dual-Luciferase Reporter Assay
Luciferase assay was performed for determining the interaction of
miR675-5p and miR22-5p with H19 and VDR. H19 fragment or
VDR 30 UTR containing the conserved miR675-5p and miR22-5p
binding sites (mutant-type namedH19-MUT, VDR-MUT containing
a mutation at the predicted miR675-5p and miR22-5p, and wild-type
named H19-WT, VDR-WT) was amplified by PCR. The PCR frag-
ment was subcloned into the psiCHECK-2 vector (Promega Corpora-
tion, Madison) according to the manufacturer’s instructions, and psi-
CHECK2 empty vector was considered as a NC. Luciferase vectors
were co-transfected into HEK293T cells with miR675-5p mimics or
miR22-5p mimics (GenePharma) using Lipofectamine 2000. As an
internal control, the Renilla luciferase reporters were also co-trans-
fected. After 48 h transfection, dual luciferase activity was measured
using the Dual-Luciferase Reporter Assay System (Promega, Madi-
son, WI) according to the manufacturer’s instructions. Relative firefly
luciferase activity was normalized to Renilla luciferase activity.402 Molecular Therapy: Nucleic Acids Vol. 19 March 2020Statistical Analysis
The normality test of continuous variables was examined by the
Kolmogorov-Smirnov test. Student’s t (bar graph) and Mann-Whit-
ney U (scatterplot) tests were used to compare continuous variables
in AS and HC groups as appropriate. Pearson’s chi-square test
was used to compare the between-group difference of categorical
variables. ROC curve and AUC were used to assess whether the
expression of lncRNA can be a biomarker of AS. Spearman’s rank
correlation coefficient test was used to explore the correlations be-
tween the expression of H19 gene and other molecules (i.e., VDR,
TGF-b, IL-17A, IL-23, and TNF-a). All statistical analyses were per-
formed by SPSS 23.0 software (SPSS, Chicago, IL, USA) and diagrams
were generated using the GraphPad Prism version 5.01 (GraphPad
Software, CA, USA). A two-tailed p value <0.05 was considered sta-
tistically significant.
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